A Phase 3 interventional study of imatinib mesilate and interferon-alpha (INF-a) in Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 163 sites in 16 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-10-14.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 1 open to participants now, 5 under way, none of them phase 3. imatinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 2nd largest by enrollment of the 83 interventional ones that give a count, is one of 6 that started in 2000, is one of 14 in phase 3, and was the 45th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →1 of the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 26 more countries
Ages 7–100
By country, each count listing its studies:
imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 56 · Phase 3 15 · Phase 4 8
First in 1999; this study’s year is marked. 6 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,106 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 60 across the 83 interventional studies. Of the 72 that completed or were terminated, 20 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 93 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one has the largest enrollment of the 63 interventional ones that give a count, is one of 5 that started in 2000, is one of 19 in phase 3, and was the 16th registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate and compare the side effects and anti-leukemic benefits of imatinib with those of interferon and Ara-C for patients who have chronic myeloid leukemia (CML) in the chronic phase. Patients in this study will be randomized (1:1) to receive either interferon plus Ara-C or imatinib as initial treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Additional protocol-defined inclusion/exclusion criteria may apply
In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10\^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m\^2/day (max 40 mg) SC injection for 10 days every month. Maximum study duration was 11.5 years.
Drug: imatinib mesilate · Drug: interferon-alpha (INF-a) · Drug: cytarabine (ARA-C)
In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m\^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10\^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571). IFN treatment was discontinued with protocol amendment 6. Maximum study duration was 8 years.
Drug: imatinib mesilate · Drug: interferon-alpha (INF-a) · Drug: cytarabine (ARA-C)
imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.
Also known as: Glivec®, Gleevec®, STI571
interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day.
Also known as: Roferon®-A, Intron®-A
cytarabine 20 mg/m\^2/day (max 40 mg) SC for 10 days every month.
Kaplan-Meier Estimates of Overall Survival (All Randomized Participants)
Overall survival was defined as the time between date of randomization and death due to any cause. The time was censored at last examination date for patients who were still being treated and at date of last contact for patients who discontinued treatment. Kaplan-Meier estimates of the percentage of participants at each time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.
Time frame: 12,24,36,48,60,72,84,96,108,120,132 and 144 months
Kaplan Meier Estimates of Event Free Survival (All Randomized Participants)
Event-free survival is defined as the time between randomization and the earliest of any of the following events on treatment: * progression to Accelerated Phase (AP) or Blast Crisis (BC) * loss of Complete Hematological Response (CHR) * loss of Major Cytogenetic Response (MCyR) confirmed * loss of Major Cytogenetic Response (MCyR) unconfirmed * increase in white blood cell count (WBC) if approved by the Study Management Committee (SMC) * death (due to any cause when reported as primary reason for discontinuation of treatment). Kaplan Meier estimates of the percentage of participants with Event Free Survival at the given time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.
Time frame: 12,24,36,48,60,72,84,96,108,120,132 and 144 months
Percentage of Participants With Event Free Survival Events (All Randomized Participants)
Event-free survival is defined as the time between randomization and the earliest of any of the following events on treatment: * progression to Accelerated Phase (AP) or Blast Crisis (BC) * loss of Complete Hematological Response (CHR) * loss of Major Cytogenic Response (MCyR) confirmed * loss of Major Cytogenic Response (MCyR) unconfirmed * increase in white blood cell count (WBC) if approved by the Study Management Committee (SMC) * death (due to any cause when reported as primary reason for discontinuation of treatment). The percentage of participants with Event Free Survival events in each category was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.
Time frame: 144 months
Kaplan Meier Estimates of Time to Progression to Accelerated Phase (AP) or Blast Crisis (BC) (All Randomized Participants)
Time to progression to AP/BC is defined as the time between randomization and either of the following events on treatment: death (due to CML when reported as primary reason for discontinuation of treatment) or progression to Accelerated Phase or Blast Crisis and is censored at last examination date for patients without event. No data after discontinuation of study treatment was included. The Kaplan Meier estimates of the percentage of participants with survival without progression to AP/BC at the given time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.
Time frame: 12,24,36,48,60,72,84,96,108,120,132 and 144 months
Percentage of Participants With Best Cytogenetic Response (First-line Treatment)
Bone marrow aspirate was performed to evaluate cytogenetic results (percentage of Philadelphia chromosome positive (Ph+) metaphases) and amount of blasts and promyelocytes in bone marrow to establish cytogenetic response. Major Cytogenetic Response= Complete Response or Partial Response. Complete Cytogenetic Response= 0 % of Ph+ metaphases (out of 20 metaphases). Partial Cytogenetic Response= \> 0 and ≤ 35 % of Ph+ metaphases (out of 20 metaphases). The percentage of participants with cytogenetic response in each category was calculated.
Time frame: 144 months
Percentage of Participants With Best Cytogenetic Response (Second-line Treatment)
Bone marrow aspirate was performed to evaluate cytogenetic results (percentage of Ph chromosome (Ph+) containing metaphases) and the amount of blasts and promyelocytes in bone marrow to establish cytogenetic response. Major Cytogenetic Response= Complete Response or Partial Response. Complete Cytogenetic Response= 0 % of Ph+ metaphases (out of 20 metaphases). Partial Cytogenetic Response= \> 0 and ≤ 35 % Ph+ metaphases (out of 20 metaphases). The percentage of participants with cytogenetic response in each category was calculated.
Time frame: 144 months
Number of Participants With Serious Adverse Events as a Measure of Safety (First-line Treatment)
A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant
Time frame: 144 months
Number of Participants With Serious Adverse Events as a Measure of Safety (Second-line Treatment)
A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant
Time frame: 144 months
Percentage of Participants With Major Molecular Response (First-line Treatment)
Major Molecular Response was determined using a quantitative polymerase chain reaction (PCR) laboratory test and was defined as BCR-ABL protein transcripts of ≤ 0.1% according to the international scale.
Time frame: 12,24,36,48,60,72,84,96,108,120,132 and 144 months
Percentage of Participants With Major Molecular Response (Second-line Treatment)
Major Molecular Response was determined using a quantitative polymerase chain reaction (PCR) laboratory test and was defined as BCR-ABL protein transcripts of ≤ 0.1% according to the international scale.
Time frame: 12,24,36,48,60,72,84,96,108,120,132 and 144 months
| Milestone | Imatinib (STI571) | IFN-a + Ara-C | Imatinib to IFN-a + Ara-C | IFN-a + Ara-C to Imatinib |
|---|---|---|---|---|
| Started | 553 | 553 | 0 | 0 |
| Safety population; received study drug | 551 | 533 | 0 | 0 |
| Completed | 267 | 7 | 0 | 0 |
| Not completed | 286 | 546 | 0 | 0 |
| Withdrew: Adverse event | 38 | 37 | 0 | 0 |
| Withdrew: Abnormal laboratory values | 3 | 1 | 0 | 0 |
| Withdrew: Abnormal procedure | 2 | 0 | 0 | 0 |
| Withdrew: Unsatisfactory therapeutic effect | 88 | 29 | 0 | 0 |
| Withdrew: No longer required study drug | 21 | 8 | 0 | 0 |
| Withdrew: Protocol violation | 17 | 17 | 0 | 0 |
| Withdrew: Subject withdrew consent | 57 | 77 | 0 | 0 |
| Withdrew: Lost to follow-up | 15 | 6 | 0 | 0 |
| Withdrew: Administrative problems | 12 | 6 | 0 | 0 |
| Withdrew: Death | 19 | 2 | 0 | 0 |
| Withdrew: Crossed over to other treatment arm | 14 | 363 | 0 | 0 |
| Milestone | Imatinib (STI571) | IFN-a + Ara-C | Imatinib to IFN-a + Ara-C | IFN-a + Ara-C to Imatinib |
|---|---|---|---|---|
| Started | 0 | 0 | 14 | 363 |
| Completed | 0 | 0 | 0 | 175 |
| Not completed | 0 | 0 | 14 | 188 |
| Withdrew: Adverse event | 0 | 0 | 3 | 34 |
| Withdrew: Abnormal laboratory values | 0 | 0 | 0 | 3 |
| Withdrew: Abnormal procedure | 0 | 0 | 0 | 1 |
| Withdrew: Unsatisfactory therapeutic effect | 0 | 0 | 9 | 70 |
| Withdrew: No longer required study drug | 0 | 0 | 1 | 14 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 10 |
| Withdrew: Subject withdrew consent | 0 | 0 | 0 | 34 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 6 |
| Withdrew: Administrative problems | 0 | 0 | 0 | 7 |
| Withdrew: Death | 0 | 0 | 0 | 9 |
Overall survival was defined as the time between date of randomization and death due to any cause. The time was censored at last examination date for patients who were still being treated and at date of last contact for patients who discontinued treatment. Kaplan-Meier estimates of the percentage of participants at each time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.
| Percentage of participants | Imatinib (STI571) | IFN-a + Ara-C |
|---|---|---|
| 12 months (n = 553, 553) | 98.9 (98 to 100) | 97.7 (96 to 99) |
| 24 months (n = 542, 512) | 96.0 | 93.6 |
| 36 months (n = 518, 471) | 92.4 | 89.8 |
| 48 months (n = 492, 441) | 90.4 | 87.7 |
| 60 months (n = 475, 411) | 89.4 | 85.4 |
| 72 months (n = 461, 388) | 88.2 | 83.8 |
| 84 months (n = 446, 373) | 86.6 | 83.1 |
| 96 months (n = 430, 358) | 85.4 | 81.4 |
| 108 months (n = 391, 315) | 84.3 | 79.9 |
| 120 months (n = 368, 299) | 83.3 | 78.8 |
| 132 months (n = 356, 288) | 82.8 | 77.7 |
| 144 months (n = 250, 199) | 81.3 | 75.4 |
Event-free survival is defined as the time between randomization and the earliest of any of the following events on treatment: * progression to Accelerated Phase (AP) or Blast Crisis (BC) * loss of Complete Hematological Response (CHR) * loss of Major Cytogenetic Response (MCyR) confirmed * loss of Major Cytogenetic Response (MCyR) unconfirmed * increase in white blood cell count (WBC) if approved by the Study Management Committee (SMC) * death (due to any cause when reported as primary reason for discontinuation of treatment). Kaplan Meier estimates of the percentage of participants with Event Free Survival at the given time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.
| Percentage of participants | Imatinib (STI571) | IFN-a + Ara-C |
|---|---|---|
| 12 months (n = 553, 553) | 96.6 | 79.4 |
| 24 months (n = 505, 332) | 89.6 | 70.0 |
| 36 months (n = 448, 263) | 85.3 | 67.0 |
| 48 months (n = 415, 241) | 83.9 | 63.7 |
| 60 months (n = 395, 223) | 83.2 | 61.9 |
| 72 months (n = 376, 207) | 83.0 | 60.1 |
| 84 months (n = 352, 181) | 82.0 | 59.0 |
| 96 months (n = 334, 166) | 81.0 | 58.3 |
| 108 months (n = 301, 141) | 79.9 | 56.6 |
| 120 months (n = 269, 130) | 79.6 | 56.6 |
| 132 months (n = 257, 124) | 79.6 | 56.6 |
| 144 months (n = 143, 76) | 79.6 | 51.8 |
Event-free survival is defined as the time between randomization and the earliest of any of the following events on treatment: * progression to Accelerated Phase (AP) or Blast Crisis (BC) * loss of Complete Hematological Response (CHR) * loss of Major Cytogenic Response (MCyR) confirmed * loss of Major Cytogenic Response (MCyR) unconfirmed * increase in white blood cell count (WBC) if approved by the Study Management Committee (SMC) * death (due to any cause when reported as primary reason for discontinuation of treatment). The percentage of participants with Event Free Survival events in each category was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.
| Percentage of participants | Imatinib (STI571) | IFN-a + Ara-C |
|---|---|---|
| Participants with events | 17.9 | 32.2 |
| Progression to AP or BC | 6.9 | 12.8 |
| Loss of CHR | 2.7 | 7.6 |
| Loss of MCyR (confirmed) | 4.2 | 5.4 |
| Loss of MCyR (unconfirmed) | 0.9 | 1.1 |
| Increase of WBC | 0.2 | 3.4 |
| Death | 3.1 | 1.8 |
Time to progression to AP/BC is defined as the time between randomization and either of the following events on treatment: death (due to CML when reported as primary reason for discontinuation of treatment) or progression to Accelerated Phase or Blast Crisis and is censored at last examination date for patients without event. No data after discontinuation of study treatment was included. The Kaplan Meier estimates of the percentage of participants with survival without progression to AP/BC at the given time point was calculated. This outcome was measured in all randomized patients, regardless of whether crossover occurred, i.e., events that occurred in patients, who had crossed over, were attributed following crossover to the original randomized treatment.
| Percentage of participants | Imatinib (STI571) | IFN-a + Ara-C |
|---|---|---|
| 12 months (n = 553, 553) | 98.5 | 92.9 |
| 24 months (n = 513, 388) | 95.7 | 90.0 |
| 36 months (n = 461, 337) | 94.0 | 87.9 |
| 48 months (n = 431, 311) | 93.1 | 84.7 |
| 60 months (n = 409, 289 ) | 92.7 | 83.5 |
| 72 months (n = 384, 265) | 92.7 | 83.1 |
| 84 months (n = 358, 236) | 92.7 | 82.4 |
| 96 months (n = 338, 220) | 92.4 | 82.4 |
| 108 months (n = 305, 189) | 92.1 | 82.4 |
| 120 months (n = 272, 175) | 92.1 | 82.4 |
| 132 months (n = 259, 165) | 92.1 | 82.4 |
| 144 months (n = 145, 94) | 92.1 | 82.4 |
Bone marrow aspirate was performed to evaluate cytogenetic results (percentage of Philadelphia chromosome positive (Ph+) metaphases) and amount of blasts and promyelocytes in bone marrow to establish cytogenetic response. Major Cytogenetic Response= Complete Response or Partial Response. Complete Cytogenetic Response= 0 % of Ph+ metaphases (out of 20 metaphases). Partial Cytogenetic Response= \> 0 and ≤ 35 % of Ph+ metaphases (out of 20 metaphases). The percentage of participants with cytogenetic response in each category was calculated.
| Percentage of participants | Imatinib (STI571) | IFN-a + Ara-C |
|---|---|---|
| Major Cytogenic Response | 89.0 | 23.3 |
| Complete Cytogenic Response | 82.8 | 11.6 |
| Partial Cytogenic Response | 6.1 | 11.8 |
Bone marrow aspirate was performed to evaluate cytogenetic results (percentage of Ph chromosome (Ph+) containing metaphases) and the amount of blasts and promyelocytes in bone marrow to establish cytogenetic response. Major Cytogenetic Response= Complete Response or Partial Response. Complete Cytogenetic Response= 0 % of Ph+ metaphases (out of 20 metaphases). Partial Cytogenetic Response= \> 0 and ≤ 35 % Ph+ metaphases (out of 20 metaphases). The percentage of participants with cytogenetic response in each category was calculated.
| Percentage of participants | Imatinib to IFN-a + Ara-C | IFN-a + Ara-C to Imatinib |
|---|---|---|
| Major Cytogenic Response | 14.3 | 86.0 |
| Complete Cytogenic Response | 7.1 | 81.0 |
| Partial Cytogenic Response | 7.1 | 5.0 |
A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant
| Participants | Imatinib (STI571) | IFN-a + Ara-C |
|---|---|---|
| Number of Participants With Serious Adverse Events as a Measure of Safety (First-line Treatment) | 226 | 163 |
A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant
| Participants | Imatinib to IFN-a + Ara-C | IFN-a + Ara-C to Imatinib |
|---|---|---|
| Number of Participants With Serious Adverse Events as a Measure of Safety (Second-line Treatment) | 2 | 160 |
Major Molecular Response was determined using a quantitative polymerase chain reaction (PCR) laboratory test and was defined as BCR-ABL protein transcripts of ≤ 0.1% according to the international scale.
| Percentage of participants | Imatinib (STI571) | IFN-a + Ara-C |
|---|---|---|
| 12 months (n= 305, 83) | 50.2 | 9.6 |
| 24 months (n= 102, 12) | 69.6 | 25.0 |
| 36 months (n= 68, 7) | 76.5 | 28.6 |
| 48 months (n= 305, 12) | 77.0 | 58.3 |
| 60 months (n= 316, 10) | 88.0 | 100.0 |
| 72 months (n= 292, 9) | 88.0 | 88.9 |
| 84 months (n= 247, 8) | 91.9 | 87.5 |
| 96 months (n= 228, 4) | 92.5 | 100.0 |
| 108 months (n= 233, 0) | 93.6 | NA |
| 120 months (n= 204, 0) | 93.1 | NA |
| 132 months (n= 168, 0) | 92.3 | NA |
| 144 months (n= 1, 0) | 100.0 | NA |
Major Molecular Response was determined using a quantitative polymerase chain reaction (PCR) laboratory test and was defined as BCR-ABL protein transcripts of ≤ 0.1% according to the international scale.
| Percentage of participants | IFN-a + Ara-C to Imatinib |
|---|---|
| 12 months (n = 86) | 51.2 |
| 24 months (n = 62) | 69.4 |
| 36 months (n = 130) | 78.5 |
| 48 months (n = 216) | 81.9 |
| 60 months (n = 174) | 86.2 |
| 72 months (n = 146) | 91.1 |
| 84 months (n = 139) | 86.3 |
| 96 months (n = 138) | 87.0 |
| 108 months (n = 120) | 90.0 |
| 120 months (n = 84) | 85.7 |
| 132 months (n = 31) | 90.3 |
| 144 months | NA |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Imatinib (STI571) | — | 226/551 (41%) | 541/551 (98.2%) |
| IFN-a + Ara-C | — | 163/533 (30.6%) | 531/533 (99.6%) |
| Imatinib to IFN-a + Ara-C | — | 2/14 (14.3%) | 13/14 (92.9%) |
| IFN-a + Ara-C to Imatinib | — | 160/363 (44.1%) | 347/363 (95.6%) |
| Event | Imatinib (STI571) | IFN-a + Ara-C | Imatinib to IFN-a + Ara-C | IFN-a + Ara-C to Imatinib |
|---|---|---|---|---|
| FatigueGeneral disorders | 3/551 | 7/533 | 1/14 | 3/363 |
| PyrexiaGeneral disorders | 19/551 | 20/533 | 1/14 | 12/363 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/551 | 11/533 | 1/14 | 2/363 |
| Bone painMusculoskeletal and connective tissue disorders | 2/551 | 6/533 | 1/14 | 2/363 |
| Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/551 | 2/533 | 1/14 | 3/363 |
| DizzinessNervous system disorders | 7/551 | 5/533 | 1/14 | 0/363 |
| PneumoniaInfections and infestations | 12/551 | 7/533 | 0/14 | 14/363 |
| Blast crisis in myelogenous leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/551 | 5/533 | 0/14 | 12/363 |
| DepressionPsychiatric disorders | 2/551 | 15/533 | 0/14 | 2/363 |
| Chest painGeneral disorders | 14/551 | 4/533 | 0/14 | 7/363 |
| Event | Imatinib (STI571) | IFN-a + Ara-C | Imatinib to IFN-a + Ara-C | IFN-a + Ara-C to Imatinib |
|---|---|---|---|---|
| FatigueGeneral disorders | 214/551 | 354/533 | 7/14 | 104/363 |
| NauseaGastrointestinal disorders | 276/551 | 325/533 | 4/14 | 138/363 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 272/551 | 63/533 | 1/14 | 168/363 |
| DiarrhoeaGastrointestinal disorders | 250/551 | 231/533 | 2/14 | 148/363 |
| HeadacheNervous system disorders | 205/551 | 231/533 | 2/14 | 87/363 |
| PyrexiaGeneral disorders | 91/551 | 217/533 | 3/14 | 42/363 |
| Decreased appetiteMetabolism and nutrition disorders | 53/551 | 207/533 | 2/14 | 18/363 |
| MyalgiaMusculoskeletal and connective tissue disorders | 131/551 | 200/533 | 4/14 | 63/363 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 173/551 | 199/533 | 3/14 | 93/363 |
| DepressionPsychiatric disorders | 84/551 | 186/533 | 3/14 | 31/363 |
| Age Continuous(years) | Imatinib (STI571) | IFN-a + Ara-C | Total |
|---|---|---|---|
| Median | 50.0 (18 to 70) | 51.0 (18 to 70) | 51.0 (18 to 70) |
| Sex: Female, Male(Participants) | Imatinib (STI571) | IFN-a + Ara-C | Total |
|---|---|---|---|
| Female | 211 | 243 | 454 |
| Male | 342 | 310 | 652 |
Showing the first 100 of 163 sites across 16 countries. Choose a country and city above to see the rest.
The record gives a start of Jun 2000, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Imatinib · Cytarabine
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →